Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

• Piero Barbanti,
• Gabriella Egeo,
• Cinzia Aurilia,
• Florindo d’Onofrio,
• Maria Albanese,
• Ilaria Cetta,
• Paola Di Fiore,
• Maurizio Zucco,
• Massimo Filippi,
• Francesco Bono,
• Claudia Altamura,
• Stefania Proietti,
• Stefano Bonassi,
• Fabrizio Vernieri,
• for the FRIEND-Study Group

Affiliations

Piero Barbanti

Headache and Pain Unit, IRCCS San Rafaele Pisana

Gabriella Egeo

Headache and Pain Unit, IRCCS San Rafaele Pisana

Cinzia Aurilia

Headache and Pain Unit, IRCCS San Rafaele Pisana

Florindo d’Onofrio

Neurology Unit, San Giuseppe Moscati Hospital

Maria Albanese

Regional Referral Headache CenterNeurology Unit, University Hospital Tor Vergata

Ilaria Cetta

Headache Unit, Department of Neurology, Scientifc Institute San Rafaele Hospital, Vita-Salute University

Paola Di Fiore

Headache Center, ASST Santi Paolo Carlo

Maurizio Zucco

Headache Center, Neurlogy Unit, San Camillo-Forlanini Hospital

Massimo Filippi

Neurology Unit, IRCCS San Rafaele Scientifc Institute, Vita-Salute San Raffaele University

Francesco Bono

Center for Headache and Intracranial Pressure Disorders, Neurology Unit, A.O.U. Mater Domini

Claudia Altamura

Headache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico

Stefania Proietti

Clinical and Molecular Epidemiology, IRCCS San Rafaele

Stefano Bonassi

Clinical and Molecular Epidemiology, IRCCS San Rafaele

Fabrizio Vernieri

Headache and Neurosonology Unit, Campus BioMedico University Hospital

for the FRIEND-Study Group